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There  is  some  evidence  in  prospective  randomized  clinical  trials  that  the  administration  of  adrenaline
(AD)  before  admission  for  the treatment  of  out-of-hospital  cardiac  arrest  did  not improve  survival  to
hospital  discharge.  The  aim  of  this  study  was  to evaluate  our real-world  experience  regarding  the efﬁcacy
of intravenous  AD  in out-of-hospital  cardiac  arrest  at  our university  hospital.  In this  retrospective  study,
we enrolled  and  divided  644  patients  into  AD (AD  administration  before  arrival  at  the  hospital)  and  non-
AD  (no  AD  administration  before  arrival  at the  hospital)  groups.  The  patient  characteristics  including  age,
sex, percentage  of  cardiac  cause,  location  of  cardiac  arrest,  and  witnessed  arrest  were  similar  between
the  AD  and  non-AD  groups.  There  were  no  signiﬁcant  differences  between  the  AD  and non-AD  groupseturn of spontaneous circulation
urvival to hospital admission
urvival to discharge
with  regard  to  return  of spontaneous  circulation,  survival  to  hospital  admission,  survival  to  hospital
discharge,  or  good  neurologic  recovery  at hospital  discharge  in  all patients.  In addition,  we excluded  the
data of  patients  with  extrinsic  cause.  We  analyzed  whether  intravenous  AD  before  arrival  in  patients  with
intrinsic  cause  was  effective.  The  outcomes  in  the  AD group  were  similar  to those  in the  non-AD  group.
In conclusion,  our  study  indicated  that  AD  administration  before  arrival  at the hospital  for  the  treatment
of out-of-hospital  cardiac  arrest  did  not  improve  the  clinical  outcome.
©  2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.. Introduction
Early access, early cardiopulmonary resuscitation (CPR), early
eﬁbrillation, and early advanced care, including the use of intra-
enous drugs, should improve survival in sudden cardiac arrest.
he administration of adrenaline (AD) has been advocated dur-
ng CPR in cardiac arrest for decades [1].  The 2005 guidelines of
oth the American Heart Association and the European Resusci-
ation Council recommend its use [2,3]. AD was shown to be an
ndependent predictor of a poor outcome in a large retrospective
egistry study [4].  AD has been shown to have beneﬁcial short-
erm effects in animal studies [5,6]. On the other hand, there
as been some concern regarding the potential harmful effects of
D on post cardiac arrest myocardial function and cerebral func-
ion, and there is little evidence from clinical trials that the use
f AD for the treatment of cardiac arrest improves survival [7,8].
∗ Corresponding author at: Department of Cardiology, Fukuoka University School
f  Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
el.: +81 92 801 1011; fax: +81 91 865 2692.
E-mail address: miuras@cis.fukuoka-u.ac.jp (S. Miura).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.07.001The survival outcomes in human studies have been controversial
[9–11].
Several prospective randomized clinical trials have recently
indicated that the use of AD before admission for the treat-
ment of out-of-hospital cardiac arrest (OHCA) did not improve
survival to hospital discharge [12,13]. In a prospective, ran-
domized controlled trial, patients with intravenous access and
drug administration had higher rates of short-term survival with
no statistically signiﬁcant improvements in survival to hospi-
tal discharge or long-term survival compared to patients who
received advanced cardiac life support (ACLS) without intra-
venous drug administration following OHCA [12]. In addition,
Jacobs et al. reported that patients who received AD during
cardiac arrest had no statistically signiﬁcant improvement in sur-
vival to hospital discharge, although there was a signiﬁcantly
improved likelihood of achieving return of spontaneous circu-
lation (ROSC) in a double-blind randomized placebo-controlled
trial [13].Therefore, in this study, we  aimed to evaluate our real-world
experience regarding the efﬁcacy of intravenous AD before arrival
at the hospital in OHCA from the Fukuoka University Registry (FU-
Registry).
vier Ltd. All rights reserved.
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. Methods
.1. Study patients and design
Six hundred forty-four patients who experienced cardiac
rrest between April 2006 and March 2011 at the Department
f Emergency and Critical Care Medicine, Fukuoka University
ospital, Fukuoka, Japan were enrolled. The enrollment was per-
ormed using our database of FU-Registry. Our protocol was
pproved by the hospital ethics committee. Patients received
ither ACLS with intravenous AD before arrival at the hospi-
al (AD group) or ACLS without intravenous AD before arrival
t the hospital (non-AD group). Intravenous AD was given after
he initiation of CPR and initial deﬁbrillation (if appropriate) fol-
owing successful placement of an intravenous line consistent
ith ACLS standards according to the modiﬁed 2005 American
eart Association guidelines [3].  The paramedics were able to
rovide ACLS and deﬁbrillation with automated external deﬁbril-
ators.
The patient characteristics (age, sex, and medical history), car-
iac arrest circumstances (arrest location, witnessed, bystander
PR, deﬁbrillation, AD given), electrocardiographic (ECG) rhythms,
mergency medical services (EMS) response times, and outcomes
ere recorded by EMS personnel and subsequently by physicians.
he ambulance crew recorded the time of arrival at the patient’s
ide, the time when CPR was started, the time of deﬁbrillation, the
ime when transport to the hospital was started, and the time of
rrival at the hospital. The immediate outcome was  reported as
ead on arrival, dead in emergency room, or admitted to hospital
live.
The initial cardiac arrest rhythm was deﬁned as ventricular
brillation (VF), pulseless ventricular tachycardia (VT), pulse-
ess electrical activity (PEA), or asystole. Shockable rhythm
as deﬁned as VF and pulseless VT. PEA and asystole are
on-shockable rhythms. The initial rhythm was based on infor-
ation obtained from the ﬁrst ECG recording after arrival of
he ambulance crew and on whether or not the patient was
eﬁbrillated..2. Study outcomes
The primary endpoint was survival to hospital discharge with
econdary endpoints of ROSC, survival to hospital admission, and
492   Adults
(Age≥18)
r
644 assessed fo
513   Cardiac arrest out-of-hospital,
Directly admission to ER 
49 AD administration 
before arrival at hospital
159 Extrinsic ca
35 AD administration 
before arrival at hospital
Fig. 1. Study proﬁle. ER, emergeiology 60 (2012) 503–507
good neurologic recovery at hospital discharge. Cerebral Per-
formance Category (CPC) at hospital discharge was used as a
neurological outcome. CPC scores are deﬁned as: 1 – normal func-
tion; 2 – mild to moderate disability; 3 – severe disability; 4 –
vegetative state; and 5 – dead. The patients with survival to hospi-
tal discharge were divided into two groups: fully awake and other.
Good neurologic recovery was deﬁned as CPC 1 or 2.
2.3. Statistical analysis
Differences in patient and study characteristics were assessed
using Pearson’s chi-square test and the t-test for categorical and
continuous data, respectively. Odds ratios (OR) and 95% conﬁ-
dence intervals were derived for primary and secondary outcomes.
Logistic regression was  used to adjust for potential confounders
on the effect of treatment with AD on primary and secondary
outcomes. Analysis was performed on an intention-to-treat basis
and per-protocol basis using StatView 5.0 statistical software.
All statistical tests were two-sided with a signiﬁcance level
of 0.05.
3. Results
3.1. Patient characteristics
Six-hundred forty-four patients who  experienced OHCA were
enrolled (Fig. 1). Of those, 131 patients were not eligible due to
insufﬁcient medical records, cardiac arrest in our hospital, and
transfer from another hospital. We  also excluded 21 patients with
age younger than 18 years. Therefore, this study included 492 adult
patients: 49 with AD administration and 443 without AD adminis-
tration. Table 1 shows the characteristics of all patients in the AD
and non-AD groups. Characteristics such as age, gender, percent-
age (%) of cardiac cause, location of cardiac arrest, initial rhythm,
and deﬁbrillation before arrival at the hospital were similar in both
groups. The incidence of witnessed cardiac arrest by bystander in
the AD group was signiﬁcantly higher than that in the non-AD
group. In patients with intrinsic cause, there were no signiﬁcant
differences in those characteristics between the groups (data not
shown). The cause of arrest in all cases is shown in Table 2. There
were 333 with intrinsic causes and 159 with extrinsic causes. There
were no differences in the cause between the AD and non-AD
groups.
21   Excluded
(Age<18) 
131   Excluded (Insufficient medical 
ecords, cardiac arrest in our hospital, 
and transferred from other hospital) 
r eligibility
443   No AD administration
before arrival at hospital
use
298  No AD administration
before arrival at hospital
ncy room; AD, adrenaline.
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Table  1
Patient characteristics.
All (n = 492) Non-AD group
(n = 443)
AD group
(n = 49)
P value
Non-AD versus AD
Age (years) 64 ± 18 64 ± 18 63 ± 18 0.882
Male,  n (%) 324 (66) 291 (66) 33 (67) 0.816
Indoor location of cardiac arrest, n (%) 379 (77) 342 (77) 37 (76) 0.79
Cardiac arrest before ambulance arrival, n (%) 443 (90) 398 (90) 45 (91) 0.658
Bystander CPR, n (%) 261 (53) 236 (53) 25 (51) 0.764
Witnessed cardiac arrest, n (%)
By bystander 167 (34) 141 (32) 26 (53) 0.003
By  ambulance crew 47 (10) 43 (10) 4 (8) 0.727
Initial cardiac arrest rhythm, n (%)
Pulseless electrical activity 139 (28) 124 (28) 15 (30) 0.706
Ventricular ﬁbrillation/tachycardia 75 (15) 63 (14) 12 (25) 0.059
Asystole 277 (56) 255 (58) 22(45) 0.087
Deﬁbrillation before arrival at the hospital, n (%) 84 (17) 71 (16) 13 (27) 0.071
Intravenous access before arrival at the hospital, n (%) 143 (29) 94 (21) 49 (100) <0.001
Onset  – call (min) 4.3 ± 6.7 4.5 ± 7.1 3.7 ± 4.1 0.527
Call  – arrival at patient’s side (min) 7.7 ± 4.2 7.6 ± 4.0 8.4 ± 5.5 0.169
Arrival at patient’s side – arrival at the hospital (min) 18.3 ± 6.3 18.4 ± 6.3 18.1 ± 6.1 0.805
Arrival at patient’s side – adrenaline i.v. (min) 23.6 ± 8.0 25.1 ± 7.1 12.3 ± 5.4 <0.001
Cardiac arrest on arrival at the hospital, n (%) 437 (89) 397 (90) 40 (82) 0.092
Cardiac arrest rhythm on arrival at the hospital, n (%)
Pulseless electrical activity 104 (24) 94 (24) 10 (24) 0.919
Ventricular ﬁbrillation/tachycardia 29 (7) 24 (6) 5 (12) 0.132
Asystole 303 (69) 278 (70) 25 (61) 0.232
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C.2. Outcomes for patients in the AD and non-AD groups
Table 3 shows the results of the analysis for primary and sec-
ndary outcomes stratiﬁed according to AD administration. In all
atients, the incidences of ROSC, survival to hospital admission,
urvival to discharge, and good neurologic recovery in the AD
roup were similar to those in the non-AD group (Table 3a). In
 comparison of the AD group to the non-AD group, the OR was
.88 for ROSC (p = 0.808) for survival to hospital admission, 1.16
p = 0.724) for survival to discharge, and 0.52 (p = 0.445) for good
eurologic recovery at hospital discharge. In addition, we also
xcluded the data of patients with extrinsic cause and analyzed
hether intravenous AD before arrival in patients with intrinsic
ause was effective in Table 3b. The outcomes in the AD group were
imilar to those in the non-AD group.
We  also evaluated the efﬁcacy of AD in patients with shockable
HCA in Table 4. In patients with shockable OHCA (all cause or
ntrinsic cause cases), the incidences of ROSC, survival to hospital
dmission, survival to discharge, and good neurologic recovery in
he AD group were similar to those in the non-AD group. Thus, there
ere no signiﬁcant differences between the AD and non-AD groups
n terms of the clinical outcomes.
able 2
ause of cardiac arrest.
All (n = 492) Non-AD group
(n = 443)
AD group
(n = 49)
Intrinsic cause, n (%) 333 (68) 298 (67) 35 (71)
Cardiologic disease 169 (34) 147 (33) 22 (45)
Respiratory disease 23 (5) 19 (4) 4 (8)
Neurological disease 22 (5) 20 (5) 2 (4)
Digestive disease 9 (2) 9 (2) 0 (0)
Others (unknown) 110 (22) 103 (23) 7 (14)
Extrinsic cause, n (%) 159 (32) 145 (33) 14 (29)
Trauma 53 (11) 50 (11) 3 (6)
Neck hanging 54 (11) 51 (12) 3 (6)
Airway trouble 28 (6) 22 (5) 6 (12)
Drowning 16 (3) 14 (3) 2 (4)
Others 8 (2) 8 (2) 0 (0)4. Discussion
AD has been a standard of ACLS care since its inception. In the
present study that considered real-world experience, the admin-
istration of AD before arrival at the hospital for the treatment of
OHCA did not improve ROSC, survival to hospital admission, sur-
vival to hospital discharge, or good neurologic recovery at hospital
discharge.
AD is thought to aid resuscitation mainly by its -adrenergic
effects. The survival outcomes in human studies have been contro-
versial [9–11]. However, the potential adverse effects of AD include
decreased total forward cardiac output, increased myocardial oxy-
gen consumption, myocardial dysfunction post-resuscitation, and
increased intrapulmonary shunting [14,15]. We  did not conﬁrm a
previous observational ﬁnding that intravenous AD was  an inde-
pendent predictor for a poor outcome [4].  Our results are consistent
with those of a multicenter study by Stiell et al., who  found no
difference in survival after implementing intravenous drug admin-
istration during OHCA [16], and two recent prospective randomized
clinical trials [12,13]. This study showed that AD administration
before admission had no signiﬁcant effect on short-term survival,
and there is no reason to expect any difference in long-term survival
or neurologic recovery.
Patients with intravenous access and drug administration had
higher rates of short-term survival (more frequently ROSC) [12].
ROSC is an increasingly important clinical endpoint regarding the
inﬂuence of post-resuscitation care interventions on survival to
hospital discharge [17,18]. Jacobs et al. clearly demonstrated that
AD was  superior to placebo for achieving ROSC [13]. A clinical study
that evaluated high-dose AD showed that it improved short-term
results without improving long-term outcomes [19]. In our study,
we found no difference in short-term effects (ROSC and survival
to hospital admission). The negative post-resuscitation effects of
AD have also been reported to be more prominent after longer,
more clinically relevant periods of cardiac arrest (e.g. 4–6 min) than
after short periods of cardiac arrest (e.g. 2 min) [20]. This differ-
ence may  have inﬂuenced our results, but we  do not have sufﬁcient
data regarding the duration of cardiac arrest. Moreover, we  did not
know the dose of AD in this study, and randomized trials of AD
506 M. Machida et al. / Journal of Cardiology 60 (2012) 503–507
Table 3
Outcomes for patients in the AD and non-AD groups in all patients (a) and patients with intrinsic cause (b).
a. All patients
Outcomes Non-AD group
(n = 443), n (%)
AD group
(n = 49), n (%)
OR (95% CI) P value
Return of spontaneous circulation (ROSC) 204 (46) 21 (43) 0.88 (0.48–1.59) 0.671
Survival to hospital admission 155 (35) 18 (37) 1.08 (0.56–1.99) 0.808
Survival to hospital discharge 64 (14) 8 (16) 1.16 (0.52–2.58) 0.724
Good  neurologic recovery at hospital discharge (CPC 1–2) 28 (44) 2 (25) 0.43 (0.08–2.29) 0.321
b.  Patients with intrinsic cause
Outcomes Non-AD group
(n = 298), n (%)
AD group
(n = 35), n (%)
OR (95% CI) P value
Return of spontaneous circulation (ROSC) 144 (48) 15 (43) 0.80 (0.40–1.63) 0.541
Survival to hospital admission 104 (35) 13 (37) 1.10 (0.53–2.28) 0.793
Survival to hospital discharge 40 (13) 6 (17) 1.33 (0.52–3.42) 0.547
Good  neurologic recovery at hospital discharge (CPC 1–2) 22 (55) 2 (33) 0.41 (0.07–2.50) 0.333
AD, adrenaline; OR, odds ratio; CI, conﬁdence interval; CPC, Cerebral Performance Category. Data of good neurologic recovery are shown in the patients with survival to
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n cardiac arrest have compared high-dose versus standard-dose
D, without reference to placebo or the non-administration of AD
21–23]. All of these trials demonstrated that high-dose AD was
uperior for achieving ROSC, however, they failed to demonstrate
etter survival to hospital discharge.
Since AD administration was not associated with the clinical
utcome, we also analyzed contributors to patient outcome in all
atients (Supplementary Figure). Logistic regression modeling was
erformed to control for the effect of potential confounders on
he relationship between AD administration and patient outcome.
ndependent predictors for ROSC were witnessed arrest and car-
iac cause and deﬁbrillation before arrival at the hospital, those for
urvival to hospital admission were witnessed arrest, cardiac cause,
nd initial shockable rhythm, that for survival to discharge was  wit-
essed arrest. Thus, in this study, witnessed arrest was a common
nd strong predictor for ROSC, survival to hospital admission, and
urvival to discharge. In addition, in patients with intrinsic cause,
itnessed arrest was a common and strong predictor for ROSC
nd survival to hospital admission (data not shown). Witnessed
rrest, but not AD administration before arrival at the hospital, may
trongly affect the clinical outcome. To support this observation,
ome trials have demonstrated that AD is superior for achieving
able 4
utcomes for patients in the AD and non-AD groups in patients with shockable OHCA.
a. All patients
Outcomes Non-AD group
(n = 63), n (%)
Return of spontaneous circulation (ROSC) 47 (75) 
Survival to hospital admission 44 (70) 
Survival to hospital discharge 29 (46) 
Good  neurologic recovery at hospital discharge (CPC 1-2) 19 (66) 
b.  Intrinsic cause
Outcomes Non-AD group
(n = 58), n (%)
Return of spontaneous circulation (ROSC) 44 (76) 
Survival to hospital admission 41 (71) 
Survival to hospital discharge 27 (47) 
Good  neurologic recovery at hospital discharge (CPC 1–2) 18 (67) 
D, adrenaline; OHCA, out-of-hospital cardiac arrest; OR, odds ratio; CI, conﬁdence interva
n  the patients with survival to hospital discharge.ROSC, however they failed to demonstrate better survival to hos-
pital discharge [22,23].
Supplementary material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.jjcc.2012.07.001.
Several studies have identiﬁed dissimilar etiologies in sub-
groups with shockable and nonshockable rhythms [24], and it
seems reasonable that there are differences in treatment strate-
gies [25]. Fifteen percent of our patients had a shockable rhythm.
Well-controlled prospective randomized clinical trials have shown
higher percentages of patients with a shockable rhythm (33% [12]
and 45% [13]). Thus, the factor of an initial shockable rhythm
was included in logistic regression modeling. An initial shock-
able rhythm was an independent predictor for survival to hospital
admission, but not for survival to discharge. However, our study
was not powered for this analysis and no conclusions should be
drawn.
In this study, there were several speciﬁc patient characteristics
and clinical outcomes compared to those as previously reported.
As noted before, the incidence of shockable rhythm was relatively
low in this study. In addition, the incidence of survival to hospital
discharge (15%) was relatively high compared to previous reports
(10% [12] and 3% [13]), and the incidence of cardiac cause (34%) was
AD group
(n = 12), n (%)
OR (95% CI) P value
7 (58) 0.48 (0.13–1.72) 0.257
7 (58) 0.61 (0.17–2.15) 0.436
3 (25) 0.39 (0.10–1.58) 0.188
2 (67) 1.05 (0.09–13.08) 0.968
AD group
(n = 11), n (%)
OR (95% CI) P value
6 (55) 0.38 (0.10–1.45) 0.156
6 (55) 0.50 (0.13–1.85) 0.298
3 (27) 0.43 (0.10–1.79) 0.246
2 (67) 1.00 (0.08–12.56) >0.999
l; CPC, Cerebral Performance Category. Data of good neurologic recovery are shown
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elatively low (70% [12] and 90% [13]). These differences may also
ffect the efﬁcacy of AD administration.
.1. Study limitations
This study has several limitations. First, it was  a retrospec-
ive clinical study and not a placebo-controlled, randomized study.
econd, we were unable to assess the inﬂuence of CPR quality
r the timing of AD administration during resuscitation on our
ndings. AD administration varied depending on the successful
stablishment of intravenous access and variations in resuscita-
ion procedures. In addition, we did not exclude the possibility
hat other drug regimens might improve the outcome. Third, sud-
en cardiac arrests were induced by intrinsic and extrinsic causes.
ntrinsic cause mainly contained cardiologic diseases, such as acute
yocardial infarction [26] and ventricular ﬁbrillation including
rugada syndrome [27]. Since we did not have enough information
bout them, it might affect the efﬁcacy of intravenous AD. Fourth,
nly 10% of the patients in this study received AD from paramedics,
hich is much less than in previous reports. This contributes to
hy the study was underpowered for the endpoint. Finally, this is
 single-center study and the results may  not be generalized to sys-
ems with different training, infrastructure, treatment protocols, or
uality of CPR.
. Conclusions
Our study indicated that the use of AD administration before
rrival at the hospital for the treatment of OHCA did not improve
linical outcomes in real-world experience at our university hospi-
al. The ﬁndings of this study are clinically important in that they did
ot support the continued use of AD in cardiac arrest as currently
ecommended.
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